Astria Therapeutics, Inc. (ATXS) Misses Q2 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/11/2026
- Wall St futures recover as oil slides ahead of inflation test
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but on track for 8% weekly gain on supply concerns; US diesel hits record high
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- White House copper tariff plan stalls amid affordability concerns, sources say
- Micron's Taiwan workers to get rewards worth up to 68 months of pay
- Crude Inventory 0.4M Barrels Last Week - EIA
- Vertiv shares drop on acquisition skepticism, AI pullback
- S&P 500, Dow futures attempt recovery ahead of inflation report
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
H.C. Wainwright Reiterates Buy Rating on Astria Therapeutics (ATXS)
August 13, 2024 6:04 AM EDTH.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and $16.00 price target on Astria Therapeutics (NASDAQ: ATXS).
The analyst comments "Clinical development of navenibart and STAR-0310 backed by positive marks and new partners. Following favorable initial proof-of-concept data from the ALPHA-STAR Phase 1b/2 clinical trial evaluating navenibart (STAR-0215) in patients with hereditary angioedema (HAE), and pending regulatory feedback, the company plans to initiate a Phase 3 study in 1Q25, with top-line data expected by YE26. Recall, ALPHA-STAR... More
